Alitair Pharmaceuticals, Inc.
Records under this name other than patents Alitair Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to Alitair Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,808,743 | Benzonatate Compositions and Methods of Use Lapsed on the fee record Ended Aug 19, 2026 · Medium confidence | Lapsed on the fee record | Ended Aug 19, 2026 | Medium confidence |
| US 8,617,602 | Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments Lapsed on the fee record Ended Dec 31, 2025 · USPTO record | Lapsed on the fee record | Ended Dec 31, 2025 | USPTO record |
| US 8,357,398 | Benzonatate Compositions and Methods of Use Lapsed on the fee record Ended Jan 22, 2025 · High confidence | Lapsed on the fee record | Ended Jan 22, 2025 | High confidence |
| US 8,187,617 | Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments Lapsed on the fee record Ended May 29, 2024 · USPTO record | Lapsed on the fee record | Ended May 29, 2024 | USPTO record |
| US 9,211,292 | Preventing or reducing drug abuse and overdose events Lapsed on the fee record Ended Dec 15, 2023 · USPTO record | Lapsed on the fee record | Ended Dec 15, 2023 | USPTO record |